Government clarifies stance on cost-effectiveness assessment of statin preparations
Published: 2008-05-21 07:00:00
Updated: 2008-05-21 07:00:00
The Health Insurance Review Agency said on May 16 that its assessment on the cost-effectiveness of new antihyperlipidemic agents is entirely based on scientific evidences, expressing its regret over miscommunication between government and industry.
In an information session, the HIRA said that...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
